Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

Clinical trial NCT06462248 · RECRUITING

Trial details

NCT number: NCT06462248
Sponsor: Chi Kong Li
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Nonhodgkin Leukemia, Lymphocytic

Start date: 2024-06-01
Primary completion: 2026-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.